Literature DB >> 10579323

Cloning of the mouse somatostatin receptor subtype 5 gene: promoter structure and function.

D F Gordon1, W W Woodmansee, S R Lewis, R A James, W M Wood, E C Ridgway.   

Abstract

Somatostatin is a peptide hormone whose actions are mediated by five somatostatin receptor subtypes (sstl-5). In the pituitary, somatostatin inhibits TSH release from thyrotropes and GH release from somatotropes. We have shown that sst5 transcripts and protein are induced by thyroid hormone in TtT-97 thyrotropic tumors. To map sequences responsible for promoter activity in pituitary cells, we cloned the mouse sst5 coding region of 362 amino acids and 12 kb of upstream DNA. Initial transfection studies in TtT-97 or GH3 cells mapped high levels of basal promoter activity to a 5.6-kb fragment upstream of the translational start, whereas shorter genomic fragments had low activity. To identify the transcriptional start site we used 5' RACE with TtT-97 poly A+ RNA and a sst5 antisense coding region primer. Sequence comparison between the complementary DNA and the gene revealed that the mouse sst5 gene contains 3 exons and 2 introns. The entire coding region was contained in exon 3. Two differently sized RACE products demonstrated alternate exon splicing of two untranslated exons in TtT-97 cells. A promoter fragment from -290/+48 linked to a luciferase reporter demonstrated 600- and 900-fold higher activity over a promoterless control in GH3 mammosomatotropes and TtT-97 thyrotropes, respectively, whereas a larger fragment extending to -6400 exhibited no additional promoter activity. Cloning of the sst5 gene will facilitate the mapping of basal and regulated responses at the transcriptional level.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579323     DOI: 10.1210/endo.140.12.7165

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 2.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

3.  Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults.

Authors:  P A Velasquez-Mieyer; P A Cowan; K L Arheart; C K Buffington; K A Spencer; B E Connelly; G W Cowan; R H Lustig
Journal:  Int J Obes Relat Metab Disord       Date:  2003-02

4.  Pituitary tumors arising from glycoprotein hormone alpha-subunit-deficient mice contain transcription factors and receptors present in thyrotropes.

Authors:  Virginia D Sarapura; William M Wood; Whitney W Woodmansee; Danielle J Haakinson; Janet M Dowding; David F Gordon; E Chester Ridgway
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

5.  Adrenaline but not noradrenaline is a determinant of exercise-induced lipid mobilization in human subcutaneous adipose tissue.

Authors:  I de Glisezinski; D Larrouy; M Bajzova; K Koppo; J Polak; M Berlan; J Bulow; D Langin; M A Marques; F Crampes; M Lafontan; V Stich
Journal:  J Physiol       Date:  2009-05-05       Impact factor: 5.182

6.  Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.

Authors:  Sunshine Daddario Axlund; Byong Hoon Yoo; Rachel B Rosen; Jerome Schaack; Peter Kabos; Daniel V Labarbera; Carol A Sartorius
Journal:  Horm Cancer       Date:  2012-11-27       Impact factor: 3.869

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.